[EN] THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS<br/>[FR] COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES ET LEUR UTILISATION COMME MODULATEURS DE PKM2
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2014074848A1
公开(公告)日:2014-05-15
Compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
[EN] ONE STEP PROCESS FOR THE PREPARATION OF PHENYL ETHYL AMINE DERIVATIVES<br/>[FR] PROCÉDÉ EN UNE ÉTAPE POUR LA PRÉPARATION DE DÉRIVÉS DE PHÉNYLÉTHYLAMINE
申请人:SYNGENTA CROP PROTECTION AG
公开号:WO2021110859A1
公开(公告)日:2021-06-10
The present invention relates to a novel process for the preparation of phenyl ethyl amine derivatives by reacting a phenyl ethyl hydroxy compound with hydrogen cyanide followed by in situ hydrolysis.
本发明涉及一种新型制备苯乙基胺衍生物的工艺,通过将苯乙基羟基化合物与氢氰酸反应,然后进行原位水解。
Fluorine-Containing Compound, Fluorine-Containing Polymer Compound, Resist Composition and Patterning Method Using Same
申请人:Mori Kazunori
公开号:US20110318542A1
公开(公告)日:2011-12-29
There is disclosed a fluorine-containing polymer compound comprising a repeating unit (a) of the following general formula (2) and having a weight-average molecular weight of 1000 to 1000000
where R
1
represents a polymerizable double bond-containing group; R
2
represents a fluorine atom or a fluorine-containing alkyl group; R
3
represents a hydrogen atom, an acid labile group, a cross-linking site or the other monovalent organic group; and W
1
represents a linking moiety.
When the fluorine-containing polymer compound is used in a resist compound for pattern formation by high energy radiation of 300 nm or less wavelength or electron beam radiation, it is possible to form a resist pattern with a good rectangular profile.
Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use
申请人:STRONGBRIDGE DUBLIN LIMITED
公开号:US10987402B2
公开(公告)日:2021-04-27
The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.